Skip to main content

Fall Protection Guidelines From USPSTF Highlight Vitamin D


May 29, 2012 — Exercise or physical therapy, along with vitamin D supplementation, are the best medicine for fall prevention among older adults, according to a report by the US Preventive Services Task Force (USPSTF). The new clinical guideline was published online May 28 in the Annals of Internal Medicine.
Virginia A. Moyer, MD, MPH, on behalf of the USPSTF, reported new recommendations for fall prevention among community-dwelling adults aged 65 years and older after reviewing evidence on both the efficacy and possible harm from interventions. Dr. Moyer and colleagues reviewed data on multifactorial clinical assessment, clinical management, clinical education or behavioral counseling, home hazard modification, and exercise or physical therapy.
Falls are the leading cause of injury in adults aged 65 years and older, with 30% to 40% of community-dwelling adults older than 65 years falling at least once each year. Among these patients, 5% to 10% incur a fracture, laceration, or head injury from a fall.
The task force called its recommendation for exercise or physical therapy a grade B recommendation, meaning the service is recommended with a high certainty of moderate benefit. On the basis of a review of 18 studies that tested exercise or physical therapy, the USPSTF estimated the risk for falls would be reduced 13% (pooled relative risk [RR], 0.87; 95% confidence interval [CI], 0.81 - 0.94). To prevent 1 person from falling, 16 people needed to undergo physical therapy or undertake exercise for 12 weeks. High-risk populations benefited most (pooled RR, 0.84; 95% CI, 0.78 - 0.91).
Similarly, vitamin D supplementation was also a grade B recommendation, with the USPSTF concluding it has moderate certainty of moderate net benefit among older adults. In a review of 9 trials involving vitamin D supplementation, the authors estimated there was a 17% reduction in the risk of falling over the course of 6 to 36 months of follow-up, with a number needed to treat of 10. When studies targeted those who were vitamin D deficient, the effect was greater yet.
In contrast, the task force did not recommended multifactorial risk assessment with comprehensive management of identified risk for the general population of older adults. The authors stressed that the service would likely be beneficial only to selected patients, depending on individual symptoms.
Specifically, a combined analysis of 6 studies on multifactorial clinical assessment with comprehensive management resulted in a non–statistically significant reduction of risk after 12 months, with a pooled RR of 0.89 (95% CI, 0.76 - 1.0). The largest of these studies involved 1559 adults with a mean age of 72.5 years reporting a 25% reduction in the risk of falling in the intervention group compared with control patients (RR, 0.75; 95% CI, 0.64 - 0.88). Multifactorial clinical assessment with less-than-comprehensive follow-up was ineffective in reducing the risk for falls (pooled RR, 0.994; 95% CI, 0.917 - 1.076).
In addition, 4 studies that looked at vision correction failed to report a reduced risk of falling, and evidence for wearing hip protection was mixed. Although 1 study of 4169 women with an average age of 78 years reported a reduced risk of falling after 12 months, a smaller study found no benefit. Evidence of the benefits of protein supplementation was limited, as was evidence for clinical education or behavioral counseling. Three studies examining home hazard modification produced results that fell short of statistical significance.
The author has disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...